MARKET OUTLOOK

Asthma pharmacotherapy has two main goals: address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals—maintenance therapy (e.g., a LABA/ICS such as GlaxoSmithKline’s Advair or AstraZeneca’s Symbicort) and rescue therapy (e.g., a SABA such as albuterol)—and most asthma patients receive more than one drug to treat their condition. Multiple well-established agents have been available for both maintenance and rescue treatment, but in the past two years, the asthma treatment landscape expanded even more with the approvals of the first branded-generic LABA/ICSFDC (i.e., Teva’s AirDuo and its generic), the first LAMA (i.e., BoehringerIngelheim’s Spiriva), and two novel biologics (i.e., GlaxoSmithKline’s Nucala and Teva’s Cinqair). These agents have expanded physicians’ treatment arsenal and fueled increasing competition in the asthma therapy market.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed asthma patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed asthma patients?
  • How have newer inhaled asthma therapies, such as Breo, Spiriva, Nucala, and Cinqair, been integrated into the treatment algorithm?
  • What proportion of asthma patients receive drug therapy within 365 days of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of asthma patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with asthma?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use in different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Table of contents

  • Asthma - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms: Claims Data Analysis in Asthma

Author(s): Elena Kozhemyakina, Ph.D.

Elena Kozhemyakina, Ph.D., is a director on the Immune and Inflammatory Disorders team at Clarivate. She manages a team of analysts generating syndicated market research products on asthma, COPD, systemic lupus erythematosus, and urticaria. Previously, Dr. Kozhemyakina completed a postdoctoral fellowship at Harvard Medical School, where she investigated molecular mechanisms involved in limb patterning, cartilage formation, and pathogenesis of osteoarthritis. She has authored multiple peer-reviewed publications on molecular signaling in developmental disorders. She received her Ph.D. from the West Virginia University School of Medicine.


Related Reports

Asthma | Disease Landscape and Forecast | G7 | 2020

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral dr...

View Details

Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Ma...

View Details

Asthma - Landscape & Forecast - Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details